高级检索
当前位置: 首页 > 详情页

A pH-responsive chiral mesoporous silica nanoparticles for delivery of doxorubicin in tumor-targeted therapy

文献详情

资源类型:
Pubmed体系:
机构: [1]Institute of Tibetan Plateau, Southwest Minzu University, Chengdu 610225, China [2]School of Pharmacy, China Medical University, Shenyang 110122, China [3]College of Pharmacy, Southwest Minzu University, Chengdu 610041, China [4]Biobank of West China Hospital of Sichuan University, Chengdu 610041, China [5]The First Hospital of China Medical University, Shenyang 110001, China
出处:
ISSN:

关键词: Chiral mesoporous silica Chitosan-modification PH-response Biosafety Anti-tumor activity

摘要:
The purpose of this study was to develop a nano-drug delivery system with intelligent stimuli-responsive drug delivery in tumor microenvironment (TME). Based on chiral mesoporous silica nanoparticles (CMSN) with a chiral recognition function in our previous research, a pH-responsive CMSN (CS-CMSN) was successfully prepared by chemical modification of chitosan (CS), and the related physicochemical properties, drug release performance, potential anti-tumor effect, and biological safety were studied. The results showed that the CS-CMSN were successfully modified by CS. Moreover, CS-CMSN displayed superior encapsulation ability for doxorubicin (DOX) and exhibited controllable pH-responsive drug release properties. In particular, in a physiological environment (pH 7.4/6.5), CS shielded the nanopores, prevented DOX release, and minimized side effects on normal cells. Once the CS-CMSN was exposed to the TME (pH 5.0), the pH-sensitive moiety of CS was cleaved in an acidic environment, along with the rapid release of DOX. In vitro cell experiments further proved that DOX@CS-CMSN was more strongly taken up by 4T1 cells and could enhance the toxicity to 4T1 tumor cells as well as promote cell apoptosis. More importantly, CS-CMSN were shown to have good biosafety in vitro and in vivo. Overall, the delivery of DOX by CS-CMSN nanocarriers is a promising strategy for tumor-targeted therapy.Copyright © 2022. Published by Elsevier B.V.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 2 区 医学
小类 | 1 区 生物物理 2 区 物理化学 3 区 材料科学:生物材料
最新[2023]版:
大类 | 2 区 医学
小类 | 1 区 生物物理 2 区 物理化学 3 区 材料科学:生物材料
第一作者:
第一作者机构: [1]Institute of Tibetan Plateau, Southwest Minzu University, Chengdu 610225, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:54705 今日访问量:2 总访问量:4648 更新日期:2025-03-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号